3 results
Approved WMOCompleted
To demonstrate the additive IOP lowering effect of SIMBRINZA (dosed BID) when added to DUOTRAV solution in subjects with open-angle glaucoma or ocular hypertension.
Approved WMOCompleted
Objective: Our main objective is to evaluate the additional effect of omega-3 fatty acids on maximal walking distance in patients with IC receiving SET. Our secondary objective is to evaluate the effect of omega-3 fatty acids on hemorheological…
Approved WMOCompleted
* To investigate the long-term safety and tolerability of ponesimod * To investigate the long-term efficacy of ponesimod* To explore the dose response relationship of 10, 20 and 40 mg ponesimod on lymphocyte count, MRI endpoints and annualized…